Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 13, 2014

KBI Biopharma Gains Biomanufacturing Facility in Colorado

  • KBI Biopharma signed an agreement with Merck to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado. Effective May 1, 2014, KBI will provide ongoing development and manufacturing services to Merck, as well as to third-party customers.

    “KBI will now offer expanded microbial development and manufacturing services up to 1,500 L scale, as well as continuing to offer our current full range of process development, analytical, and formulation development and mammalian manufacturing services up to 2,000 L,” said Joe McMahon, president and CEO of KBI. KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.

    According to McMahon, KBI has helped to advance more than 220 molecules in 55 different health indications for over 170 clients around the world.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »